medication treatment

Methylphenidate extended‑release (Concerta) is a first‑line stimulant medication for adult ADHD. It works by blocking dopamine and noradrenaline transporters in the prefrontal cortex, raising synaptic concentrations of these two neurotransmitters and thereby improving executive functions such as sustained attention, impulse control and working memory (Bolea‑Alamañac et al., 2014). Although the drug can relieve symptoms for many diagnosed patients, stimulant‑based pharmacotherapy has notable limitations and risks, which are often under‑represented in online community experience‑sharing.

Common clinical side‑effects include decreased appetite, dry mouth, headache, insomnia, irritability, elevated heart rate and blood pressure, as well as mood lability. A small subset of patients may develop tics or exacerbated anxiety (Food and Drug Administration, 2026). Research findings on stimulant tolerance remain mixed. Systematic reviews suggest that universal long‑term pharmacological tolerance does not occur in all patients. Still, some individuals experience gradual loss of therapeutic effect over months or years, requiring dose increases to maintain symptom control (Handelman & Sumiya, 2022). Once the maximum clinically safe dose is reached, further dose escalation yields no additional benefits, leaving limited pharmaceutical options for these patients. True pharmacological tolerance should also be distinguished from confounding factors including fluctuating stress levels, poor sleep, comorbid anxiety‑depression and developmental symptom changes, all of which may create the subjective impression that “the medication no longer works”.

Stimulants are controlled psychotropic substances and must be prescribed and monitored by qualified psychiatrists. Self‑medication, unsupervised dose increases and off‑label use carry risks of dependence and cardiovascular harm. Medication cannot cure ADHD. International clinical guidelines consistently recommend combined pharmacotherapy and cognitive‑behavioural interventions rather than medication‑only management (Kooij et al., 2019).

ADHD is a neurodevelopmental disorder, instead of a problem caused by poor willpower or laziness. To date no single definite cause has been established; the condition arises from the interaction of genetics, brain circuit features and neurotransmitter regulation (Chinese Society of Psychiatry, 2023).

Neuroimaging studies show relative developmental delay in the prefrontal cortex among ADHD populations. This brain region governs executive functions: sustained attention, impulse inhibition, working memory, planning and delayed gratification. Dysfunction within prefrontal‑striatal circuits weakens top‑down regulatory capacity, resulting in distractibility, impulsivity and difficulty completing long‑term tasks (Shaw et al., 2007).

At the neurotransmitter level, ADHD is characterised by dysregulated dopamine and noradrenaline systems, rather than simply insufficient dopamine. Abnormal transporter‑mediated re‑uptake prevents stable neurotransmitter concentrations within prefrontal synapses. During dull, low‑reward tasks, the brain fails to generate sustained neural signals for concentration, while highly stimulating, instantly rewarding stimuli readily capture attention (Arnsten, 2006).

This basis explains the therapeutic effect of stimulants such as Concerta. By inhibiting dopamine and noradrenaline transporters, stimulants reduce neurotransmitter re‑uptake and temporarily elevate synaptic transmitter levels in the prefrontal cortex to enhance executive performance (Arnsten, 2006). However, medication only adjusts short‑term neurochemical conditions; it cannot repair developmental circuit deficits in the brain. Symptoms therefore return after drug discontinuation, which accounts for why ADHD cannot be cured by medication alone.